Category list : Antineoplastic agents
Sort by: Newest first Oldest first A-Z Z-A
-
Combination drug approved in Europe for metastatic colorectal cancer
A new combination oral treatment, Lonsurf, has been granted a marketing authorisation for adults with metastatic colorectal cancer by the European Commission.
-
Alectinib approved by FDA for ALK-positive lung cancer Subscription
Alectinib, a new drug for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer, has been approved by the US Food and Drug Administration.
-
Don't overlook opportunities to repurpose existing drugs Subscription
More needs to be done to incentivise research into new indications for existing medicines.
-
Avastin indicated for cervical cancer Subscription
Avastin (bevacizumab;Roche) is now licensed, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. This is in addition to its use in advanced non-small cell lung cancer or advanced cancers of the bowel, breast or kidney.
-
NSAIDs may help protect against skin cancer Subscription
The use of non-steroidal anti-inflammatory drugs (NSAIDs), a class of medicines used to treat pain and inflammation, is associated with a reduced risk of developing cutaneous squamous cell carcinoma (SCC), a type of skin cancer, research suggests.
-
Chemoprevention with tamoxifen cuts risk of breast cancer by almost 30% Subscription
Tamoxifen used in primary prevention cuts the risk of breast cancer by around 30% and this benefit lasts for at least 20 years, a long-term follow-up of the International Breast Cancer Intervention Study shows.
-
Lipophilic bisphosphonates used to target lung cancer Subscription
A new generation of lipophilic bisphosphonates has been designed to target cancer, with a zoledronic acid analogue demonstrating efficacy against lung adenocarcinoma.
-
Ibrutinib launched for treatment of mantle cell lymphoma and chronic lymphocytic leukaemia Subscription
Ibrutinib, a Bruton’s tyrosine kinase inhibitor, has been launched in the UK for the treatment of mantle cell lymphoma or chronic lymphocytic leukaemia.
-
Clinical Pharmacist's monthly news round-up: the top 10 in the past month Subscription
What has been happening in the world of pharmacy? Here’s our pick of must-read news from the past month…
-
Criticism voiced over new rules for Cancer Drugs Fund Subscription
Cancer charities and the pharmaceutical industry have expressed concerns over the way cancer medicines are appraised after a revised process for assessing drugs available through the Cancer Drugs Fund was published by NHS England.
Show 10 per page20 per page50 per page
